BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Danvilostomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Danvilostomig\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06668961-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT06668961)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of SI-B001+SI-B003 Com
 bined With Platinum-based Chemotherapy as First-line Treatment in Patients
  With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstim
 ated primary completion: November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/danvilostomig#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06668961
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668858-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 1/2 readout est. (NCT05668858)
DESCRIPTION:Danvilostomig\, phase 1/2.\nStudy: A Study of SI-B001+SI-B003±
  Chemotherapy in Patients With Locally Advanced or Metastatic Head and Nec
 k Squamous Cell Carcinoma\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/danvilostomig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05668858
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949606-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 1/2 readout est. (NCT05949606)
DESCRIPTION:Danvilostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Adv
 anced or Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 nvilostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05949606
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006169-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT06006169)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of BL-B01D1\, SI-B003 
 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Nec
 k Squamous Cell Carcinoma and Other Solid Tumors\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 danvilostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06006169
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008054-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT06008054)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of SI-B003\, BL-B01D1+
 SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Adv
 anced or Metastatic Esophageal Cancer\, Gastric Cancer\, Colorectal Cancer
  and Other Gastrointestinal Tumors\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/danvilostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0600
 8054
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05965856-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT05965856)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of SI-B003 and BL-B01D
 1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carci
 noma and Other Solid Tumors\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/danvilostomig#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05965856
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990803-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT05990803)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of BL-B01D1\, SI-B003 
 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Can
 cer and Other Gynecological Malignancies\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/danvilos
 tomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05990803
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Danvilostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced o
 r Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcinoma and Oth
 er Solid Tumors\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/danvilostomig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05956587
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042894-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT06042894)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of SI-B003 or BL-B01D1
 +SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metas
 tatic HER2 Negative Breast Cancer\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/danvilostomig#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06042
 894
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05924841-2065@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT05924841)
DESCRIPTION:Danvilostomig\, phase 2.\nStudy: A Study of BL-B01D1\, SI-B003 
 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Canc
 er\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/danvilostomig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05924841
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
